Pyxis Oncology (PYXS) Other Accumulated Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Other Accumulated Expenses data on file, last reported at $4.0 million in Q4 2025.

• Quarterly Other Accumulated Expenses fell 37.2% year-over-year to $4.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.0 million (down 37.2% YoY) and the FY2025 annual result came in at $4.0 million, down 37.2% from the prior year.
• Other Accumulated Expenses retreated to $4.0 million in Q4 2025 per PYXS's latest filing, from $6.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $17.4 million in Q4 2022 and bottomed at $2.4 million in Q4 2021.
• The 5-year median for Other Accumulated Expenses is $6.4 million (2024), against an average of $7.4 million.
• The widest annual swing landed in 2022, when Other Accumulated Expenses soared 631.37%; it then plunged 62.13% in 2023.
• Tracing PYXS's Other Accumulated Expenses over 5 years: stood at $2.4 million in 2021, then soared by 631.37% to $17.4 million in 2022, then sank by 62.13% to $6.6 million in 2023, then dropped by 3.47% to $6.4 million in 2024, then tumbled by 37.2% to $4.0 million in 2025.
• Per Business Quant, the three latest PYXS Other Accumulated Expenses figures stand at $4.0 million (Q4 2025), $6.4 million (Q4 2024), and $6.6 million (Q4 2023).

Peer Comparison